Inflammatory Bowel Disease (IBD) Treatment Market is Expected to Reach $15.5 bn by 2027

The Inflammatory Bowel Disease (IBD) treatment market share was US$ 11.38 Bn in the year 2018. The market is anticipated to grow at a rate of 3.94%, through the forecast period to reach US$ 15.5 Bn by the year 2027.

Inflammatory Bowel Disease (IBD) usually denotes disorders characterized by the inflammation in the digestive system. Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome are two different disorders that are often confused with each other. IBS is neither characterized by inflammation nor causes damage to the bowel tissues.

IBD is categorized into Crohn’s disease (CD) & Ulcerative Colitis (UC). CD can affect the digestive tract right from the mouth to the rectum. CD appears in patches, can penetrate and affect multiple layers and organs associated with the digestive tract. Conversely, UC is continuous, limited to inflammation of colon and rectum, and inner lining of the colon. IBD is debilitating with symptoms such as weight loss, fatigue, abdominal pain, and diarrhoea. Adverse conditions can lead to mortality too. There are no defined causes for the occurrence of IBD, yet it can be attributed to defects in the immune system or can be hereditary.

The overall worldwide incidence rates are about 380-400 cases per 100,000 individuals. In the US alone, more than 3.2 million adults suffer from IBD, while in the EU, the affected population is about 2.1 million. The incidence of IBD in Asia is the lowest with rates of about 5 per 100,000 individuals. Individuals aged over 45 are more susceptible to acquire IBD. Among the two types of IBD, UC is more common with an incidence rate of about 1-25.5 cases per 100,000 while that of CD is about 0.2-18 cases per 10,000 individuals. IBD does not have a disparity amongst the male and female populations across the globe, nevertheless, UC more commonly occurs in the US male population than in the female. With the number of incidences of ulcerative colitis, the particular segment is rapidly increasing with more treatment modalities under development. Also, the prevalence is more in US and EU countries, hence, the North American region followed by the EU region contributes more to the growth of the IBD treatment market. Besides, the presence of major market players and the healthcare infrastructure is expected to further fuel the market growth. Asia Pacific region, though a less contributive region, is anticipated to increase its contribution towards the growth of the market owing to change in lifestyle and eating habits.

According to the study conducted by the Crohn’s & Colitis Foundation for ten years from 2007-2016 confirmed that the average treatment costs incurred for IBD had increased tremendously over the past 5 years. Further, it is noticed the current average treatment cost is about $26500. This is considered as one of the major restraints that will hamper the growth of the market. Also, the diagnosis of IBD is difficult due to it having more common symptoms associated with other similar diseases. Besides, the awareness of IBD was also poor, however, initiatives from government and NGOs are seeding the knowledge of IBD and its symptoms among people which is an encouraging sign for the growth of the market.

The current treatment regimens of IBD consists of injectables and oral therapies wherein injectables are preferred due to its efficacy. TNF inhibitors which are expected to subside the inflammation is more preferred injectable therapeutic form and dominated the market share. Nevertheless, the companies are focusing to develop an efficacious oral therapy owing to the ease of use. Aminosalicylates which are used for treating mild or moderate IBD dominated the oral segment. In recent years, the development of biosimilars is underway, which could offer a cost-effective treatment contributing to market growth.

Optima Insights provides the latest update on the industry trends, products & pipeline analysis with country, regional and global revenue forecast till the year 2027. The analysis of the market is segmented into Type (Crohn’s Disease & Ulcerative Colitis); Administration Injectables (TNF inhibitors, Interleukin inhibitors, Anti-integrin) & Oral (Aminosalicylates, Corticosteroids, JAK inhibitors); Distribution Channel (Hospital, Retail, Online) & Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Request for Sample Pages @

Major companies which develop drugs for Inflammatory Bowel Disease Market include Johnson & Johnson, Pfizer, Takeda Pharmaceuticals, Sanofi, Abbott, Biocon, F. Hoffman La Roche, Quest Medicals, Novartis, Mylan, AbbVie Inc, Celltrion, Celgene, Cosmo Pharmaceuticals, Innovate Biopharmaceuticals, Gilead, UCB Pharma, and many more

Research Scope

•    Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.

•    Provides a Comparative Analysis of Key Marketed and Pipeline Products.

•    Provides Key Information on Players involved.

•    Provides a Complete Overview of Market Segments and the Regional Outlook.

•    Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.

The Report Provides Key Insights on

  • History of the Inflammatory Bowel Disease, 2015 to 2019

  • Forecast of the Inflammatory Bowel Disease Growth till the year 2027

  • The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Inflammatory Bowel Disease (IBD) Market

  • Analysis of potential growth segments which will drive the market

  • Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market

  • Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Download Complete TOC of the Report @

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.


Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)